MR
Mersana Therapeutics, Inc.
MRSN · NASDAQ
$29.74 +2.42% (+$0.70)
Market Cap $145.2M
P/E Ratio -
Div. Yield -
ROE 183.15%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
41 /100
Fair P/S 4.38x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Rev. growth 880.21%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 99.14%
Net margin 211.22%
Op. margin 203.06%
Quality
37 /100
Average ROIC 310.35%
ROE 183.15%
ROA 111.80%
Debt
60 /100
Moderate Current ratio 1.39x
Int. coverage -24.52x
Net debt/EBITDA 0.82x
Stability
37 /100
Moderate Beta 0.43x
Rev. volatility 35,617.90%
EPS volatility 26.22%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MRSN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Martin H. Huber
Employees
102
Headquarters
Cambridge